Background: Early diagnosis of pancreatic cancer is essential to optimize treatment strategies.
Objectives: To evaluate the diagnostic performance of contrast-enhanced ultrasound for benign and malignant pancreatic neoplasms.
Data sources: Pubmed, Embase, Web of Science, and Cochrane Library databases.
Study eligibility criteria: Retrospective or prospective studies.
Participants: Patients with a confirmed diagnosis of benign and malignant pancreatic neoplasms.
Intervention: Contrast-enhanced ultrasound.
Study appraisal and synthesis: Pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic risk ratio, and corresponding 95% confidence intervals; summary receiver operating characteristic (SROC) curve; a Fagan nomogram.
Results: Ten studies involving 641 patients were included. Pooled sensitivity, specificity, and positive and negative predictive values were 91% (95% CI: 87%, 93%), 87% (95% CI: 78%, 93%), 7.2 (95% CI: 4.3, 12.3), and 0.11 (95% CI: 0.08, 0.15), respectively; and the odds ratio for diagnosis was 67 (95% CI: 34, 113). Contrast-enhanced ultrasound had good diagnostic ability and accuracy. Pre- and post-test probability of disease was 50% and 88%, respectively, when the positive likelihood ratio was 7.
Conclusion: Contrast-enhanced ultrasound can be used for qualitative diagnosis of benign and malignant pancreatic neoplasms. (c) 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
[1]Jilin Univ, China Japan Union Hosp, Changchun, Jilin, Peoples R China.
(8.0+极速模式)